The global viral inactivation market is projected to reach USD 573.0 million by 2021 from USD 320.5 million in 2016, at a CAGR of 12.3% from 2016 to 2020. The major drivers for the market include increase in pharmaceutical and biological industries and increasing number of new drug launches. Over the years, the number of drug approvals in North American countries has increased from 2006 to 2015. In 2015, the FDA’s Center for Drug Evaluation and Research (CDER) approved 45 novel drugs, approved as new molecular entities (NMEs) under New Drug Applications (NDAs) or as new therapeutic biologics under Biologics License Applications (BLAs) as compared to 22 novel drugs approved in 2006. The increasing number of drug approvals will boost the viral inactivation market.
According to OECD estimates, in 2011, the total number of biotechnology companies in the U.S. was 7,970, followed by Spain (3,025 biotechnology companies), and France (1,481 biotechnology companies). Owing to the rise in the number of biotechnology companies, biopharmaceutical production has increased globally. Viral inactivation is carried out at all levels of pharmaceutical and biopharmaceutical manufacturing process to minimize the risk of product contamination. Growth in pharmaceutical and biotechnology industries will drive the growth of the viral inactivation market.
This report segments the global viral inactivation market is segmented based on method, product, application, end user, and geography. The method segments included in the report are solvent detergent method, pasteurization, and other methods. Other viral inactivation method includes low pH, microwave heating, irradiation, and high-energy light.
The product segments included in the report are kits and reagents, services, and viral inactivation systems and accessories.
The application segments included in the report are blood & blood products, cellular & gene therapy products, stem cell products, tissue & tissue products, and vaccines and therapeutics.
Based on end user this market is categorized into pharmaceutical and biotechnology companies, contract research organizations, academic research institutes, and other end users.
The geographic segments included in this report are Asia, Europe, North America and the Rest of the World (RoW). North America is further divided into Canada and the U.S. Asia is further divided in to China, Japan, India, and Rest of Asia.
The report provides qualitative insights on key market shares, growth rates, and market drivers for all important subsegments. It maps market sizes and growth rates of each subsegment and identifies segments poised to see rapid growth. The report also includes company profiles of market leaders. These company profiles include the financial performances, product portfolios, and developments of each company. The report also provides a competitive landscape of the viral inactivation market. The competitive landscape covers the growth strategies adopted by industry players over the last three years. It also includes analyses of industry developments like mergers and acquisitions, agreements and partnerships, and new product launches.
Reasons to Buy the Report:
The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.
The report provides insights on the following:
- Product Development/Innovation: Product portfolios of top players in the viral inactivation market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the viral inactivation market
- Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of leading players in the viral inactivation market
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various viral inactivation products across geographies
- Market Diversification: Exhaustive information about new products and services, recent developments, and investments in the viral inactivation market